Price: quote on request. Your total cost is quoted in writing per case.
We reply within one business dayGet my quote

Myelodysplastic syndromes (MDS): US-approved treatments and how Gulf families can access them

Creator: Reserve Meds
Published: 2026-10-17

A plain guide for families in the Gulf, checked against US FDA labels, Gulf drug registers and published medical research.

Reviewed by the Reserve Meds clinical operations team on 17 October 2026.

Myelodysplastic syndromes: the short answer

The US FDA has approved four medicines on this page for myelodysplastic syndromes, each for specific patients. Three of them are on at least one Gulf register we checked, so ask your hospital about local supply first. Otherwise the hospital can request a named-patient import. Reserve Meds is a digital health company. We do not diagnose or prescribe.

US FDA-approved medicines on this page: Reblozyl, Rytelo, Revlimid and Inqovi.
Gulf registration (checked 17 October 2026): see each medicine below.
Legal route: Local supply where listed; otherwise a named-patient import request filed by the treating hospital.
Price: Quote on request.

What is myelodysplastic syndromes?

In myelodysplastic syndromes (MDS), stem cells in the bone marrow do not mature into healthy blood cells, and many die in the marrow. This leaves too few healthy cells and can lead to infection, anemia or easy bleeding.^[1]

MDS often causes no early symptoms and is sometimes found on a routine blood test. Symptoms can include shortness of breath, weakness or tiredness, pale skin, easy bruising or bleeding, small spots under the skin and fever or frequent infections.^[1]

MDS is rare. People at higher risk are over 60, have had chemotherapy or radiation, or were exposed to certain chemicals. Treatment can include transfusions, drug therapy, chemotherapy and stem cell transplants. Several US medicines target anemia in lower-risk MDS.^{[1, 2, 3]}

Myelodysplastic syndromes in the Gulf

A 10-year review at Bahrain's oncology referral center found that MDS made up 12.5% of primary bone marrow cancers in Bahraini nationals, with a median age at diagnosis of 56 and an age-standardized incidence of 0.85 per 100,000 per year.^[4]

US FDA-approved medicines for myelodysplastic syndromes

Each medicine below is approved in the US for a specific group of patients. The wording summarizes the current US label. Your specialist decides whether any of them is right for the patient.

Reblozyl (luspatercept)
FDA-approved for anemia in adults with very low- to intermediate-risk MDS who may need regular red blood cell transfusions, in specific situations listed in the label. It is also approved for beta thalassemia. It is an injection under the skin.^[2]
Gulf registers: Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.^{[5, 6]}
Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman, Egypt, India
Rytelo (imetelstat sodium)
FDA-approved for adults with low- to intermediate-1 risk MDS with transfusion-dependent anemia (4 or more red blood cell units over 8 weeks) who have not responded to, have lost response to, or cannot use erythropoiesis-stimulating agents. It is given by intravenous infusion.^[3]
Gulf registers: Saudi Arabia: not found by brand name in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.^{[5, 6]}
Country guides: Saudi Arabia, Egypt, Pakistan
Revlimid (lenalidomide)
FDA-approved for transfusion-dependent anemia due to low- or intermediate-1-risk MDS with a deletion 5q abnormality. It is a capsule. It is also approved for multiple myeloma and some lymphomas.^[7]
Gulf registers: Saudi Arabia: not found by brand name in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.^{[5, 6]}
Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman, Egypt
Inqovi (cedazuridine and decitabine)
FDA-approved for adults with MDS, including previously treated and untreated, de novo and secondary MDS of the subtypes listed in the label. It combines decitabine and cedazuridine in a tablet.^[8]
Gulf registers: Saudi Arabia: not found by brand name in the SFDA drugs list. Abu Dhabi: not found by brand name in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.^{[5, 6]}

How families in the Gulf can access these medicines

If the medicine is listed in your country. Ask your specialist and the hospital pharmacy about local supply first. A listing does not mean every hospital stocks the medicine, and another brand of the same medicine may also be registered, but local supply is usually the fastest route and you may not need us.

If it is not registered. The usual legal route is a named-patient request: the treating hospital, on your specialist's written request, asks the national regulator for permission to import the medicine for one patient, using the US FDA approval as the reference. In Saudi Arabia the SFDA Special Access Program guidance covers these requests; in Bahrain, NHRA Circular 41 of 2020 sets the procedure. Other Gulf countries have their own procedures, which the hospital pharmacy confirms.^{[9, 10]} Once approval is in place, Reserve Meds arranges supply through a US-licensed pharmaceutical wholesale partner to the hospital pharmacy.

Who does what

Your treating specialist decides whether a medicine is right for the patient and writes the letter.
The hospital checks local supply, files any import request, and gives the treatment safely.
The national regulator decides whether to approve the import of a medicine that is not registered.
The manufacturer decides where its medicine can be supplied, especially for cell and gene therapies.
Reserve Meds helps organize records, coordinates US supply through our wholesale partner, shipping and updates to your family. We do not give medical advice.

Documents you will usually need

A letter from the treating specialist with the diagnosis, past treatments and why the medicine is being considered
Reports that confirm the diagnosis, such as laboratory, genetic, imaging or pathology results, translated into English where needed
Recent clinic notes and a list of current medicines
For a hospital import request: the prescription, the hospital's request form and the written consent of the patient or guardian
Proof of the US FDA approval and the US prescribing information (we can supply these)

We give you a written timeline estimate once we see the hospital file. The regulator, the treatment center and the manufacturer set their own timelines.

What treatment costs

Quote on request. Your total cost depends on the medicine, the dose, shipping, import steps and coordination. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.

How Reserve Meds helps

Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We help your doctor and hospital prepare the file, arrange US supply and temperature-controlled shipping once approval is in place, and keep your family updated. We coordinate access to FDA-approved medicines only. Investigational medicines are only available through a manufacturer's expanded-access program requested by the treating physician; we can explain that route, but we do not supply them.

Ask us about treatment for myelodysplastic syndromes

Tell us the medicine, your country and a WhatsApp or phone number. We reply within one business day. On WhatsApp we usually reply the same day.

Frequently asked questions

Is there an FDA-approved treatment for myelodysplastic syndromes?

Yes. The medicines on this page have US FDA approval for specific groups of patients: Reblozyl, Rytelo, Revlimid and Inqovi. The exact conditions are in each US label and are summarized above. Your specialist decides whether any of them fits.

Is Reblozyl available in Saudi Arabia or the UAE?

Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register. A listing in Abu Dhabi does not show federal UAE status.

How can a family in the Gulf get Reblozyl?

Ask the treating hospital about local supply first. If it is not available, the hospital can file a named-patient import request with the national regulator on your specialist's written request. Once approved, we arrange US supply to the hospital pharmacy.

How much does treatment cost?

Quote on request. Your total cost, including the medicine, shipping, import steps and coordination, is quoted in writing for your case before you commit. No hidden charges.

Why does the risk group matter?

US labels such as Reblozyl, Rytelo and Revlimid are limited to lower-risk MDS groups and specific transfusion needs. Your hematologist assigns the risk group after bone marrow tests.

Who is more likely to get MDS?

MedlinePlus notes higher risk in people over 60, people who had chemotherapy or radiation, and people exposed to certain chemicals.

Sources for the last two answers: ^{[2, 3, 7]} ^[1]

Sources

Checked on 17 October 2026. Labels, registers and regulator rules change. Your hospital pharmacy confirms the current position before filing.

This page is general health information, not medical advice. It does not replace a consultation with your doctor.